Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02653105

Women at Risk of Breast Cancer and OLFM4

Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial

Official title:
Evaluation of the Circulating Concentration of Olfactomédine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging

Clinical Trial Summary

Does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?

Clinical Trial Description

About 5% of breast cancers are associated with the presence of a constitutional genetic alteration. Two genes are being studied: BRCA1 and BRCA2.

The national program for breast cancer screening target women 50 to 74 years but does not include women with significant risk factors. However in identifiable risk situations, breast cancer incidence is increased: and it affects 1 in 4 women with certain risk histological lesions and more than 1 in 2 women carrying a mutation in the BRCA1 or BRCA2 gene.

Studies have shown that the olfactomédine 4 (OLFM4) is highly overexpressed in tumors compared to healthy tissue. The OLFM4 might therefore be a marker for early detection of breast cancer. We wish to determine the positive predictive value of OLFM4 seric dosing of patients at risk with respect to imaging. ;

Study Design

Related Conditions & MeSH terms

  • Hereditary Breast and Ovarian Cancer Syndrome
Clinical Trial Details
NCT number NCT02653105
Study type Interventional
Source Institut Cancerologie de l'Ouest
Contact Magali BALAVOINE
Phone 2 41 35 29 31
Email magali.balavoine@ico.unicancer.fr
Status Recruiting
Phase N/A
Start date March 8, 2016
Completion date February 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00535119 - Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Phase 1
Recruiting NCT03294343 - Risk-Reducing Surgeries for Hereditary Ovarian Cancer N/A
Completed NCT02956681 - Statewide Communication to Reach Diverse Low Income Women N/A
Completed NCT00305695 - Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Phase 2
Active, not recruiting NCT03832985 - Pediatric Reporting of Adult-Onset Genomic Results Early Phase 1
Active, not recruiting NCT02760849 - Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations N/A
Completed NCT01367639 - Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Phase 2
Completed NCT02562170 - Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Phase 4
Recruiting NCT03162276 - Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Phase 3
Not yet recruiting NCT01445275 - Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 N/A
Recruiting NCT03015376 - Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Enrolling by invitation NCT04197856 - Direct Information to At-risk Relatives N/A
Completed NCT03784859 - Tissue Expansion in Breast Reconstruction Without Drains
Completed NCT04544501 - Enhance the Use of Genetic Counseling and Testing in Latinas N/A
Completed NCT00609505 - Telemedicine vs. Face-to-Face Cancer Genetic Counseling N/A
Terminated NCT02705924 - Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk N/A
Completed NCT01333748 - Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer Phase 2
Completed NCT00892736 - Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Phase 1
Recruiting NCT05677048 - Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention N/A